UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1035-12
Program Prior Authorization/Notification
Medication Gattex® (teduglutide [rDNA origin]), for injection, for subcutaneous use
P&T Approval Date 2/2013, 11/2013, 11/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019,
9/2020, 9/2021, 9/2022, 9/2023, 9/2024
Effective Date 12/1/2024
1. Background:
Gattex® (teduglutide) is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of
adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are
dependent on parenteral support.
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Initial Authorization
1. Gattex will be approved based upon both of the following criteria:
a. Diagnosis of Short Bowel Syndrome (SBS)
-AND-
b. Dependent on parenteral support
Authorization will be issued for 12 months.
B. Reauthorization
1. Gattex will be approved based on the following criterion:
a. Documentation of positive clinical response to Gattex therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. Reference:
1. Gattex [package insert]. Lexington, MA: Takeda Pharmaceuticals, Inc.; February 2024.
Program Prior Authorization/Notification - Gattex (teduglutide [rDNA origin])
Notification
Change Control
2/2013 New criteria.
11/2013 Formatting update. Removal of dose information in Background
Section.
11/2014 Annual review. Increased reauthorization approval duration to 60
months.
11/2015 Annual review. Revised initial authorization criteria to remove 12
consecutive months of PN/IV support therapy.
9/2016 Annual review. Reduced reauthorization approval duration to 24
months. Updated reference.
9/2017 Annual review. No changes.
9/2018 Annual review. No changes.
9/2019 Annual review. Updated background and references. No changes to
criteria.
9/2020 Annual review. No changes to criteria.
9/2021 Annual review with no changes to criteria. Updated references.
9/2022 Annual review. Added state mandate footnote. Updated
reauthorization duration to the standard 12 months.
9/2023 Annual review with no changes to criteria. Updated reference.
9/2024 Annual review. Updated initial authorization duration to 12 months.
Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2